Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Pompe Disease Market Insight - DelveInsightThe Pompe disease treatment market is experiencing significant expansion, driven by increasing di ...

Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

DelveInsight's, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ ...

BOSTON & MONTREAL, June 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for ...

Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dystrophy care, targeting broader ages and mutations. We are witnessing the fastest pivot in rare-disease ...

JMP Securities Silvan Tuerkcan revised the firm’s view on Taysha Gene Therapies, Inc. (NASDAQ:TSHA), raising the price target from $5 to $6 while keeping a Market Outperform rating. The update ...

Dyno’s AI-designed capsids improved therapeutic gene delivery to eye, muscle and CNS compared to commonly used AAV capsids, showcasing improved delivery efficiency, target-organ specificity and ...

Dyno Therapeutics Launches Three Breakthrough Capsid Delivery Vectors for Next-Generation Eye, Muscle and CNS Gene Therapies at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ...

Astellas Gene Therapies is based in South San Francisco, with manufacturing and laboratory facilities in South San Francisco, Calif., Sanford, N.C. and Tsukuba, Japan.